Merck: CHMP gives green light for Keytruda in pleural mesothelioma

(CercleFinance.com) - Merck announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for the approval of Keytruda (pembrolizumab), in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adults with unresectable malignant non-epithelioid pleural mesothelioma.


This recommendation is based on the results of a pivotal study (IND.227/KEYNOTE-483), which showed 'a significant improvement in overall survival compared with chemotherapy alone'.

The European Commission's final decision is expected in the fourth quarter of 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.